Journal
FRONTIERS IN ONCOLOGY
Volume 12, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2022.866013
Keywords
immunotherapy; programmed cell death protein-1 inhibitor; tislelizumab; isolated kidney; urothelial carcinoma
Categories
Funding
- Natural Science Foundation of Guangdong Province [2019A1515011454]
- Zhanjiang Science and Technology Plan Project [2019A01028, 2020A01022]
- Research Foundation for Advanced Talents of Affiliated Hospital of Guangdong Medical University [20401Z20190003]
Ask authors/readers for more resources
The discovery of immune checkpoint inhibitors (ICIs) has made significant progress in fighting against malignant tumors. This case suggests that a PD-1 inhibitor (tislelizumab) alone may be an effective treatment strategy for solitary renal calyceal urothelial carcinoma.
The discovery of immune checkpoint inhibitors (ICIs) represents a significant step forward in the battle against malignant tumors. In a number of advanced malignancies, ICIs, such as antibodies to programmed cell death protein-1 inhibitor (PD-1) and its ligand, programmed death-ligand 1 (PD-L1), have shown good therapeutic benefits. A 71-year-old male patient was diagnosed with solitary renal calyceal urothelial cancer. The space-occupying lesion in the upper calyx of the left kidney dramatically decreased after 13 treatments with a PD-1 inhibitor (tislelizumab) alone, and the tumor reached partial remission. This case suggests that a PD-1 inhibitor (tislelizumab) alone may be an effective treatment strategy for solitary renal calyceal urothelial carcinoma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available